Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

Summary

The purpose of the study is to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is given in combination with cabozantinib in adult patients with confirmed advanced or metastatic clear cell Renal Cell Carcinoma who have experienced progression on or after prior anti-PD-1 or anti-PD-L1 immunotherapy.

Eligibility

Inclusion Criteria:

* Unresectable and measurable locally advanced or metastatic renal cell carcinoma with a primary clear cell component.
* A Karnofsky Performance Status (KPS) score ≥ 80%
* At least 1 target lesion measurable by computed tomography/magnetic resonance imaging per RECIST 1.1, not within a field of prior radiation therapy.
* Adequate organ and marrow function, ≤ 1 week prior to randomization.
* Women of childbearing potential (WOCBP) must have a negative serum pregnancy test.

Exclusion Criteria:

* Received prior treatment with a HIF-2α inhibitor or cabozantinib.
* Other prior malignancy active within the previous year except for locally curable cancers that have been apparently cured.
* Ongoing clinically significant toxicities related to any prior anticancer treatment, or toxicities Grade ≥ 3 per National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI CTCAE v5.0) regardless of relatedness to prior anticancer therapies.
* Uncontrolled or poorly controlled hypertension, defined as a sustained blood pressure \> 150 mmHg systolic or \> 90 mmHg diastolic despite optimal antihypertensive treatment.
* History of leptomeningeal disease or spinal cord compression.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Conditions3

Interventions2

Locations40 sites

Find trials near these locations

Related trials

• A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033) — Merck Sharp & Dohme LLC
• A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. — Centre Leon Berard
• CARE1 Pragmatic Clinical Trial — Gustave Roussy, Cancer Campus, Grand Paris
• Cabozantinib Dose Skipping as an Alternative to Dose Reductions — dr. Tom van der Hulle
• Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors — National Health Research Institutes, Taiwan
• Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma — Gustave Roussy, Cancer Campus, Grand Paris
• Cabozantinib to Treat Recurrent Liver Cancer Post Transplant — University Health Network, Toronto
• Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer — West China Hospital

Browse More Trials